Lia Chebeleu, MD
Neurology · Vineyard, UTNPI 1174727739
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Abbott at 47.2% of the total. Reporting peaked in 2023 at $2,285 and has fallen 99.3% since, to $15 in 2025.
Across 136 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AbbVie$285
- Johnson & Johnson$237
- Nevro Corp.$195
- Boston Scientific$178
- Amgen$143
- plus $1K from 24 others
What the payments were for
- Travel & lodging$1,77143%
- Food & beverage$2,24555%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $1,942 |
| AbbVie(2 entities) | 18 | $285 |
| Johnson & Johnson | 12 | $237 |
| Nevro Corp. | 6 | $195 |
| Boston Scientific | 9 | $178 |
| Amgen | 9 | $143 |
| Lundbeck LLC | 7 | $113 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| Endo Pharmaceuticals Inc. | 6 | $93 |
| Bristol Myers Squibb | 5 | $88 |
| Biogen | 5 | $81 |
| AstraZeneca(2 entities) | 5 | $71 |
| Amneal Pharmaceuticals LLC | 5 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Argenx US, Inc. | 3 | $65 |
| Novartis | 3 | $51 |
| Acadia Pharmaceuticals Inc | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 3 | $39 |
| Pfizer | 2 | $35 |
| CSL Behring | 1 | $30 |
| EMD Serono, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Grifols USA, LLC | 1 | $22 |
| Adamas Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Strongbridge US Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Merck | 1 | $12 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$1,876
How this compares
$4,112 in reported general payments places this provider in the 65th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZonegranZonisamide | 12 | $30,858 |
| KeppraLevetiracetam | 17 | $11,432 |
| Rivastigmine | 17 | $3,338 |
| Memantine Hcl | 66 | $1,851 |
| CarbatrolCarbamazepine | 14 | $1,770 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 74 | $1,105 |
| Donepezil Hcl | 77 | $619 |
| Gabapentin | 48 | $581 |
| Atorvastatin Calcium | 19 | $511 |
| Trazodone Hcl | 37 | $343 |
| Topiramate | 27 | $330 |
| Cyclobenzaprine Hcl | 38 | $269 |
| Mirtazapine | 16 | $263 |
| Sertraline Hcl | 14 | $255 |
| Duloxetine Hcl | 26 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $6914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 157 neurology providers in Utah.
Other neurology in Vineyard
- Timothy WestSalt Lake City$856K
- Richard HammondOgden$707K
- Jeffrey GrovesDraper$628K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Yashma PatelLehi$251K
- Albert SmithSalt Lake City$122K
- Trevor SquireOgden$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.